期刊文献+

稳定型心绞痛患者冠状动脉介入治疗术前强化他汀治疗对心肌损伤的保护作用 被引量:12

下载PDF
导出
摘要 目的观察术前应用不同负荷剂量阿托伐他汀钙对稳定型心绞痛患者经皮冠状动脉介入治疗(PCI)术后心肌损伤的保护作用。方法将210例择期PCI的冠心病患者分为两组,强化他汀组100例术前1周使用阿托伐他汀钙60 mg/d,对照组110例术前1周使用阿托伐他汀钙20 mg/d,观察两组患者治疗前后血脂、肝功能,PCI术前、术后心脏生化标志物、高敏C反应蛋白(hsCRP)等指标变化及PCI术后30 d内主要不良心脏事件(MACE,包括心源性死亡、心肌梗死和靶血管血运重建)的发生率。结果强化他汀组治疗1周后总胆固醇较对照组显著降低[-1.05±0.84)mmol/L vs(-0.26±0.52)mmol/L,P=0.015],PCI术后24 h肌酸激酶同工酶、肌钙蛋白I、hsCRP均较对照组显著降低(P<0.01),PCI术后30 d内强化他汀组MACE明显少于对照组(10.0%vs22.7%,P=0.013),主要源于与PCI相关的心肌梗死明显少于对照组(10.0%vs 20.9%,P=0.030)。结论选择性PCI术前1周使用大剂量阿托伐他汀钙60 mg/d与常规剂量20 mg/d比较能更有效地减少与手术相关的心肌损伤及术后30 d MACE。
出处 《广东医学》 CAS CSCD 北大核心 2014年第18期2920-2923,共4页 Guangdong Medical Journal
基金 南宁市科学研究与技术开发计划项目(编号:zc2010007c)
  • 相关文献

参考文献24

  • 1BRENER S J, ELLIS S G, SCHNEIDER J, et al. Frequency and long - term impact of myonecrosis after coronary stenting[ J ]. Eur Heart J, 2002, 23(4) : 869 -876.
  • 2ABDELMEGUID A E, TOPOL E J, WHITLOW P L, et al. Sig- nificance of mild transient release of creatine - kinase MB fraction after percutaneous coronary interventions[J]. Circulation, 1996, 94(8) : 1528 - 1536.
  • 3CARLO B, GABRIELLA V, AMELIA F, et al. Impact of a single high loading dosa of atorvastatin on periprocedural myocardia| In- farction[ J]. J Am Coil Cardiol, 2009, 54(23) : 2164 -2166.
  • 4DI SCIASCIO G, PATH G, PASCERI V, et al. Efficacy of ator- vastatin reload in patients on chronic statin therapy undergoing per- cutaneous coronary intervevtion : results of the ARMYDA - RECAP TURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial[ J]. J Am Coil Cardiol, 2009, 54 (6) : 558 -565.
  • 5PATH G, PASCERI V, COLONNA G, et al. Atorvastatin pre- treatment improve outcomes in patients with acute coronary syn- dromes undergoing eayly percutaneous coronary intervention: re- suits of the ARMYDA -ACS randomized trial[ J]. J Am Coil Car- diol, 2007, 49(2) : 1272 - 1278.
  • 6THYGESEN K, AIPERT J S, JAFFE A S, et al. Third universal definition of myocardial infarction[J]. Global Heart, 2012, 7(4) : 275 - 295.
  • 7HAMER M, CHIDA Y, STAMATAKIS E. Utility of C - reactive protein for cardiovascular risk stratification across three age groups in subjects without existing cardiovascular diseases[ J]. Am J Car- diol, 2009, 104(4) : 538 -542.
  • 8KOENIG W, SUND M, FROHLICH M, et al. C - Reactive pro- tein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middleaged men: results from the MONICA ( Monitoring Trends and Determinants in Cardi- ovascular Disease) Augsburg Cohort Study, 1984 to 1992 [ J]. Circulation, 1999, 99(2): 237-242.
  • 9MASERI A. Inflammation, atherosclerosis, and ischemic events - exploring the hidden side of the moon[J]. N Engl J Med, 1997, 336(14) : 1014 -1016.
  • 10ROSS R. Atherosclerosis is an inflammatory disease [ J ]. AmHeart J, 1999, 138(2) : 419 -420.

同被引文献88

引证文献12

二级引证文献98

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部